Endo Breaks Off Deal To Acquire Somerset And Wintac

Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.